On May 31, 2026 Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, reported that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response rate (ORR) in patients with Late-line refractory hepatocellular carcinoma (HCC). The data, selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, highlight a potential new benchmark for patients who have exhausted standard therapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Hepatocellular carcinoma (HCC) remains a critical global health challenge, particularly in China, which accounts for more than one-third of the world’s over 800,000 annual deaths from the disease. While frontline treatments have evolved, options for patients failing second-line therapy are scarce, with historical ORRs typically below 13%.
Oricell’s registrational Phase Ib BEACON study challenges this status quo. As of April 3, 2026, among 18 efficacy-evaluable patients with advanced, heavily pretreated HCC:
Overall ORR reached 50%.
At the Recommended Phase 2 Dose (RP2D), ORR surged to 66.7%, with a disease control rate (DCR) nearing 90%.
Durability was profound: One patient achieved a complete response (CR) lasting 24 months.
Safety was manageable: No immune effector cell-associated neurotoxicity syndrome (ICANS) or off-tumor toxicity was observed, with cytokine release syndrome (CRS) contained within controllable grades.
Long-Term Validation: From 2021 ASCO (Free ASCO Whitepaper) Poster to Registrational Data
Notably, as early as 2021, Oricell’s investigator-initiated trial (IIT) data for Ori-C101 were selected for a poster presentation at ASCO (Free ASCO Whitepaper). At that time, a striking response was observed in a late-line HCC patient following a single infusion: the first efficacy assessment showed a partial response (PR), with target lesions shrinking by 96.1% (from 155.45 mm to 6 mm) and alpha-fetoprotein (AFP) levels plummeting by 99.1% (from >80,000 ng/mL to 742 ng/mL). The patient achieved an overall survival (OS) of nearly three years.
The now-unveiled registrational clinical data further validate the clinical value of Ori-C101, reinforcing the consistency and reproducibility of Oricell’s approach from early proof-of-concept to pivotal trials.
Technology Backbone: A "Three-in-One" Engine Addressing Solid Tumor Barriers
Ori-C101’s exceptional performance stems from Oricell’s proprietary technology platforms, systematically addressing major challenges in CAR-T therapy for solid tumors: antigen heterogeneity, immunosuppressive tumor microenvironment (TME), and manufacturing efficiency.
1. OriAb (AI-Powered Antibody Discovery Platform）
The OriAb platform features a massive library comprising up to 10¹¹ fully human scFv and nanobody sequences. Utilizing a live-cell-based high-throughput screening strategy, the platform specifically identifies native conformational antigens, including challenging targets such as GPCRs, thereby avoiding the false-positive risks associated with purified protein-based screening. Furthermore, AI-assisted algorithms have compressed the antibody discovery and screening cycle from a traditional 12 months to just 3 months, significantly enhancing both efficiency and quality. The resulting high-specificity, optimally affine GPC3 antibody sequence equips Ori-C101 with a robust safety profile, effectively minimizing the risk of off-tumor toxicity.
2. OriArmoring (Structure-Enhanced Cell Platform)
The OriArmoring platform incorporates customized "armoring" elements designed to modulate T cell metabolic pathways and signal transduction based on the specific tumor microenvironment (TME). This engineering strategy enriches young, stem-like memory T cell subsets (Tscm), significantly enhancing the in vivo persistence of Ori-C101. By remodeling the local immune microenvironment, the platform effectively reverses immunosuppression, converting "cold tumors" into "hot tumors," thereby promoting the infiltration and activation of effector T cells. This approach overcomes the dual bottlenecks of the immunosuppressive TME and T cell exhaustion in solid tumors, ensuring durable, long-term responses. Additionally, the platform integrates logic-gating strategies—including ‘OR’ gating to prevent antigen escape and ‘AND’ gating to improve targeting precision—which collectively optimize the therapeutic index of the product.
3. OriOnGo: Flexible Manufacturing Platform (Classic / Rapid / In Vivo)
Built on a "Quality by Design" (QbD) philosophy, this platform includes proprietary manufacturing technologies. The rapid manufacturing process reduces ex vivo culture time to just 3 days, significantly improving productivity and lowering cost of goods (COGS). It ensures final product cell viability consistently above 95%, and compresses the vein-to-vein time to within 15 days. Moreover, the platform’s in vivo CAR-T product design and process capabilities open broader future applications for CAR-T therapy. This integrated manufacturing approach enables scalable, cost-effective production while maintaining product quality and patient access.
Executive Outlook
"Securing a third ASCO (Free ASCO Whitepaper) oral presentation validates our integrated platform strategy," said Dr. Helen Yang, Co-Founder and CEO of Oricell. "We are accelerating the pivotal Phase II development to bring this therapy to market. We are also actively seeking global partnerships to expand the reach of our technology and deliver hope to patients worldwide."
(Press release, OriCell Therapeutics, MAY 31, 2026, View Source;oricells-gpc3-car-t-ori-c101-hits-66-7-orr-in-late-line-hcc-signaling-best-in-class-potential-302786638.html [SID1234666262])